CVS Health (CVS)
NYSEHealth CareHealthcare PlansSnapshot 2026-07-08
$104.44+0.11%
Close 2026-07-08 · 1-day change
Reading CVS? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track CVS free→NYSEHealth CareHealthcare PlansSnapshot 2026-07-08
Reading CVS? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track CVS free→QuarterlyIQ Insights · CVS
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 12 valuation methods, at three horizons. Current price $104.44. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $104 CVS trades at 15× p/e, below its 27× p/e peer median. Our $110 fair value sits above the price. We hold it with medium confidence: the peer anchor overstates how cheap it looks. Analysts target $92–$115. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $106.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $30.21 | — | — | Hist. CAGR | high |
| graham number | 12M | $98.27 | — | — | TTM | high |
| Mgmt guidance | 12M | $162.19 | 25.6 | 6.34 | Mgmt | high |
| Peer EV/EBITDA |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$92.00 – $115.00 (median $106.00) · 15 analysts · as of 2026-07-07
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Richer than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| 12M |
| $96.43 |
| 15.2 |
| 9.23 |
| TTM |
| high |
| Peer P/FCF | 12M | $115.17 | 19.9 | 5.78 | TTM | high |
| Peer P/E | 12M | $180.86 | 25.6 | 7.07 | TTM | high |
| Peer P/S | 12M | $1029.75 | 3.2 | 318.92 | TTM | high |
| PEG | 12M | $242.37 | 34.3 | 7.07 | TTM | high |
| residual income | 12M | $70.35 | — | — | TTM | high |
| Own P/E history | 12M | $84.57 | 12.0 | 7.07 | TTM | high |
| triangulated | 12M | $189.40 | 25.6 | 7.40 | Triangulated | high |
| Mgmt guidance | 3Y | $228.98 | 25.6 | 8.95 | Mgmt(prov.) | medium |
| Peer P/FCF | 3Y | $48.96 | 19.9 | 2.46 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $171.66 | 25.6 | 6.71 | Analyst | medium |
| Peer P/S | 3Y | $861.76 | 3.2 | 266.90 | guidance | medium |
| PEG | 3Y | $230.04 | 34.3 | 6.71 | Analyst | medium |
| Own P/E history | 3Y | $80.27 | 12.0 | 6.71 | Analyst | medium |
| Mgmt guidance | 5Y | $288.17 | 25.6 | 11.26 | Mgmt(prov.) | medium |
| Peer P/FCF | 5Y | $27.68 | 19.9 | 1.39 | Hist. CAGR(prov.) | medium |
| Peer P/E | 5Y | $129.58 | 25.6 | 5.07 | Analyst | medium |
| Peer P/S | 5Y | $650.51 | 3.2 | 201.47 | guidance | medium |
| PEG | 5Y | $173.65 | 34.3 | 5.07 | Analyst | medium |
| Own P/E history | 5Y | $60.59 | 12.0 | 5.07 | Analyst | medium |